Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
about
New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesIdentification and characterization of ambroxol as an enzyme enhancement agent for Gaucher diseaseGaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.Fabry disease - current treatment and new drug development.X-ray and biochemical analysis of N370S mutant human acid β-glucosidase.Pharmacological chaperone therapy for lysosomal storage diseases.Azasugar inhibitors as pharmacological chaperones for Krabbe diseaseInduced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher diseaseCoformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry MiceTreating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.Pharmacological small molecules for the treatment of lysosomal storage disorders.Pharmacological chaperone therapy for Gaucher disease: a patent review.Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology.Treatment options for lysosomal storage disorders: developing insights.Glucocerebrosidase inhibitors for the treatment of Gaucher disease.Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblastsHuman Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.
P2860
Q28068142-117DB631-49F2-4855-ACAB-90C1AEEA764FQ33478327-C7AACF9C-9C99-4C2E-954B-3CDD40E5983CQ34066863-41916E78-4F65-4894-97A3-2BEDA669E5C0Q34345151-D7643097-51F5-4A5A-A730-A2BBB8553B37Q34368512-F35AA686-0F37-4BDB-BA07-F42347216B46Q34452544-68963B77-F518-4147-951B-09603813D6CDQ35214286-0DAA7513-275A-45EB-BE1D-8B882B3297FEQ35652295-D0B0EB04-5005-48C9-9660-A0E1ACF30403Q36398099-F6D6BC1E-C7F4-4550-8374-9DC49F9A3C60Q36756784-64B14C70-97F2-440F-A53C-4068CFFE1028Q37668227-68BCF1E7-4D85-4F36-97F1-AFC099384263Q37799818-4908F93C-7F0A-4382-B63C-E1A9A988EF26Q37860332-5C76D459-F2C8-4388-9596-3495ACC31799Q38027408-4347F3B1-14DD-42AC-93FB-4E245582F43AQ38046227-CF21D885-6026-4A9E-8A9A-784FEE3375E3Q38097869-53131477-B48E-4EF2-972A-6AA4943BA452Q38162958-DAADE41D-E848-4BEC-B917-421325DF5276Q38424066-FE9C0C9B-3F54-41A8-AF1B-55E808590C23Q39081905-10F85344-3368-4E49-AE1A-2523644B2C4CQ39508157-BA7A4B41-E04C-42C0-9590-79A2DE5C9493Q40533569-7AA2C34E-A939-4310-8F69-EBC1FEE862AFQ41912890-740419AA-1AB2-47D7-AD4F-D4E673AD2148Q42238272-5EC631F3-0C92-40E4-A9B9-0541A8A98438
P2860
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@ast
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@en
type
label
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@ast
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@en
prefLabel
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@ast
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@en
P2093
P2860
P1476
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase.
@en
P2093
Gary J Murray
Jin-Song Shen
Nancy J Edwards
Young Bin Hong
P2860
P304
P356
10.1016/J.BBRC.2008.02.125
P407
P577
2008-03-06T00:00:00Z